EVEREST MED Achieves Favorable Outcome in Patent Protection for Nefecon®

Stock News

Feb 27

On February 27, EVEREST MED (01952) announced a significant development in the patent protection of its innovative product, budesonide enteric-coated capsules (Nefecon®). The Guangzhou Intellectual Property Court issued a civil ruling on February 26, 2026, fully supporting the company's application for pre-litigation conduct preservation. The court ordered relevant generic drug manufacturers to immediately cease infringement activities and withdraw their products from public procurement lists. The ruling took effect immediately upon issuance. EVEREST MED welcomed the court's fair decision and stated it will continue to protect intellectual property rights in accordance with the law, promoting access to innovative therapies for more patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1113601668"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113601668\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113601668?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 15:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113601668","market":"sh","top_or_hot":-1,"title":"EVEREST MED Achieves Favorable Outcome in Patent Protection for Nefecon®","media":"Stock News","content":"<p>On February 27, EVEREST MED (01952) announced a significant development in the patent protection of its innovative product, budesonide enteric-coated capsules (Nefecon®). The Guangzhou Intellectual Property Court issued a civil ruling on February 26, 2026, fully supporting the company's application for pre-litigation conduct preservation. The court ordered relevant generic drug manufacturers to immediately cease infringement activities and withdraw their products from public procurement lists. The ruling took effect immediately upon issuance. EVEREST MED welcomed the court's fair decision and stated it will continue to protect intellectual property rights in accordance with the law, promoting access to innovative therapies for more patients.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EVEREST MED Achieves Favorable Outcome in Patent Protection for Nefecon®</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEVEREST MED Achieves Favorable Outcome in Patent Protection for Nefecon®\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-27 15:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On February 27, EVEREST MED (01952) announced a significant development in the patent protection of its innovative product, budesonide enteric-coated capsules (Nefecon®). The Guangzhou Intellectual Property Court issued a civil ruling on February 26, 2026, fully supporting the company's application for pre-litigation conduct preservation. The court ordered relevant generic drug manufacturers to immediately cease infringement activities and withdraw their products from public procurement lists. The ruling took effect immediately upon issuance. EVEREST MED welcomed the court's fair decision and stated it will continue to protect intellectual property rights in accordance with the law, promoting access to innovative therapies for more patients.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1113601668","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113601668","pubTimestamp":1772177554,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On February 27, EVEREST MED (01952) announced a significant development in the patent protection of its innovative product, budesonide enteric-coated capsules (Nefecon®). The Guangzhou Intellectual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","01952":"云顶新耀","BK1583":"高瓴概念","BK1574":"生物医药B类股"},"translate_title":"EVEREST MED在Nefecon专利保护方面取得良好成果®","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1},"content_text":"On February 27, EVEREST MED (01952) announced a significant development in the patent protection of its innovative product, budesonide enteric-coated capsules (Nefecon®). The Guangzhou Intellectual Property Court issued a civil ruling on February 26, 2026, fully supporting the company's application for pre-litigation conduct preservation. The court ordered relevant generic drug manufacturers to immediately cease infringement activities and withdraw their products from public procurement lists. The ruling took effect immediately upon issuance. EVEREST MED welcomed the court's fair decision and stated it will continue to protect intellectual property rights in accordance with the law, promoting access to innovative therapies for more patients.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}